Integrated analysis of clinical, bioelectrical and functional variables in newly diagnosed lung cancer adult patients: pilot study

Table 2 Mean ± standard error of the mean of sEGF, CYFRA21-1, and CA 72–4 tumor marker values for apparently healthy subjects and newly diagnosed lung cancer adult patient

Age groups (years)	Gender	N	Tumor biomarkers
Age groups (years)	Gender	N	sEGF (pg/mL)	sCYFRA 21–1 (ng/mL)	sCA 72–4 (U/mL)
46–60	M	6	653.91 ± 162.69 (998.40 ± 71.18; N₁ = 18)	2.76 ± 1.81	7.21 ± 4.25
	F	3	1015.36 ± 309.01 (1025.00 ± 47.63; N₁ = 19)	8.29 ± 2.54	12.69 ± 5.76
	M + F	9	779.39 ± 147,21 (1012.00 ± 41.85; N₁ = 37)	4.60 ± 1,58	9.04 ± 1,11
61–80	M	8	759.75 ± 160.40 (899.00 ± 65.08; N₁ = 14)	3.41 ± 1.20	6.24 ± 1.67
	F	6	453.39 ± 86.89 (901.60 ± 80.86; N1 = 16)	3.77 ± 1.28	6.27 ± 1.66
	M + F	14	628.45 ± 104.63 (900.30 ± 51.86; N₁ = 30)	3.57 ± 0.84	6.25 ± 1.14
46–80	M	14	718.25 ± 110.66 (954.90 ± 49.18; N₁ = 32)	3.13 ± 0.99	6.66 ± 2.33
	F	9	640.71 ± 140.92 (968.80 ± 45.64; N₁ = 35)	5.28 ± 1.24	8.41 ± 2.25
	M + F	23	687.21 ± 85.31 (962.20 ± 33.22; N₁ = 67)	3.97 ± 0.79	7.34 ± 1.45

M Male gender, F Female gender, N Total number of newly diagnosed lung cancer adult patients, N₁ Total number of apparently healthy adult subjects, sEGF Serum Epidermal Growth Factor, sCYFRA 21–1 Serum CYFRA 21-1 and sCA72–4 Serum CA72–4. Averages ± standard errors of the mean of sEGF for apparently healthy adult subjects, by age group and gender, (between bracket) were reported in.¹⁴ Normal ranges of sCYFRA 21–1 (0,1–3,30 ng/mL) and sCA72–4 (0,1–6,90 U/mL) were reported in²

ISSN: 2396-832X